Combo Products Face Costlier Process Under Europe’s New MDD – Alcon Exec
This article was originally published in The Gray Sheet
The combination product policy outlined in the proposed revisions to Europe's Medical Devices Directive is emerging as a leading industry concern
You may also be interested in...
Comments from AdvaMed and its European counterpart Eucomed raise concerns about device reclassifications appearing in the revised Medical Devices Directive
A draft revision of the European Medical Devices Directive would give manufacturers of implantable and Class III devices less leeway to avoid clinical evaluation requirements
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.